» Articles » PMID: 11551032

Optimization of Culture Conditions to Enhance Transfection of Human CD34+ Cells by Electroporation

Overview
Specialty General Surgery
Date 2001 Sep 12
PMID 11551032
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The ability to culture CD34+ stem cells, while maintaining their pluripotency, is essential for manipulations such as gene transfection for therapeutic trials. Human peripheral blood (PB) CD34+ cells (> or = 90% purity) were cultured for up to 4 days in serum-free culture medium supplemented with thrombopoietin (TPO), stem cell factor (SCF), Flt-3 ligand (Flt-3L), with or without PIXY321 (IL-3/GM-CSF fusion protein) and human serum. The CD34 mean fluorescence intensity (MFI) and cell cycle status were evaluated daily using flow cytometry and hypotonic propidium iodide. Prior to culture (day 0), 97.0 +/- 0.9%, 1.9 +/- 0.3% and 1.0 +/- 0.6% of the selected CD34+ cells were in G0-G1, S-phase, or G2-M, respectively. After 2-4 days in culture with TPO/SCF/Flt-3L, there was an increase in the percent of cells in S-phase to 26.4 +/- 0.1% without significant loss of CD34 MFI. The addition of PIXY321 increased.the percentage of CD34+ cells in S-phase to 36.3 +/- 4.0%, but the CD34 MFI and numbers of CFU (colony-forming units) were significantly decreased at day 3 when cultured with PIXY321 or various recombinant cytokine combinations that included IL-3 and IL-6. There is an increase from day 0 to day 4 in the percentages of CD34+ with CD38-, HLA-DR-, and c-kit(low), but not Thy-1+ cells. Electroporation with EGFP reporter gene showed that 1-2 days of pre-stimulation in X-VIVO 10 supplemented with TPO/SCF/Flt-3L was necessary and sufficient for efficient transfection. Flow cytometry analysis demonstrated that 22% of the viable cells are CD34+/EGFP+ 48 h post electroporation. The introduced reporter gene appears to be stable as determined by EGFP+/LTC-IC (long-term colony-initiating cells), at 30-40 positive colonies (16 +/- 7%) per 1 x 10(5) electroporated CD34+ cells.

Citing Articles

Isolation and Culture of Non-adherent Cells for Cell Reprogramming.

Andrianto , Pikir B, Suryawan I, Hermawan H, Harsoyo P J Stem Cells Regen Med. 2022; 18(1):21-26.

PMID: 36003658 PMC: 9379358. DOI: 10.46582/jsrm.1801004.


Preclinical evaluation for engraftment of CD34 cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models.

Uchida N, Li L, Nassehi T, Drysdale C, Yapundich M, Gamer J Cell Rep Med. 2021; 2(4):100247.

PMID: 33948577 PMC: 8080237. DOI: 10.1016/j.xcrm.2021.100247.


¹⁹F MRI tracer preserves in vitro and in vivo properties of hematopoietic stem cells.

Helfer B, Balducci A, Sadeghi Z, OHanlon C, Hijaz A, Flask C Cell Transplant. 2012; 22(1):87-97.

PMID: 22862925 PMC: 6542565. DOI: 10.3727/096368912X653174.


Functional interactions between erythroid Krüppel-like factor (EKLF/KLF1) and protein phosphatase PPM1B/PP2Cβ.

Yien Y, Bieker J J Biol Chem. 2012; 287(19):15193-204.

PMID: 22393050 PMC: 3346094. DOI: 10.1074/jbc.M112.350496.


Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.

Sumiyoshi T, Holt N, Hollis R, Ge S, Cannon P, Crooks G Hum Gene Ther. 2009; 20(12):1607-26.

PMID: 19689196 PMC: 4094131. DOI: 10.1089/hum.2009.109.